纵横研报
Archive · Page 04 / 35

更早研报

第 4 页 · 按发布时间倒序聚合。

1021Reports · 942Tickers · 196Industries
·汽车零部件 ·内部研究

Zhejiang Shuanghuan Driveline: A Precision-Gear Cash Engine Carrying a Still-Optional Robot-Reducer Bet

Zhejiang Shuanghuan Driveline is a precision-gear specialist whose profit still comes from automotive transmission and e-drive gears, with robot RV reducers (housed in 61.29%-owned Huandong, now seeking a STAR Market listing) as a still-speculative second engine. Four straight years of rising revenue (CNY 9.11bn in 2025) and attributable profit (CNY 1.262bn), with operating cash flow above net income every year, make the transition credible, yet Q1 2026 recurring profit fell 4.04% and the loudest humanoid-customer claims stay unverified in primary filings. Rating Hold: the auto-gear cash engine is real and the reducer option is credible, but at CNY 39.42 the price already capitalizes much of that optionality, leaving no obvious margin of safety.

002472.SHE Zhejiang Shuanghuan Driveline Co., Ltd. #精密齿轮#机器人减速器#新能源车#人形机器人#估值
Hold
·制药 ·内部研究

Kelun-Biotech: A Commercializing China ADC Franchise Priced for Much of Its sac-TMT and MSD Global Success

Kelun-Biotech is a commercial-stage China ADC developer whose equity value is dominated by its sac-TMT (TROP2) franchise in Greater China plus ex-China royalty economics from MSD. In 2025 product sales inflected to RMB542.7m within RMB2.06bn total revenue and the balance sheet held RMB4.56bn cash with no borrowings, yet the company still posted a RMB382.0m net loss as nearly all equity value concentrates in one molecule. Rating Hold: a real ADC franchise is forming, but at HK$419 the stock already prices in much of the sac-TMT China plus MSD global success path and offers no margin of safety.

6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. #创新药#ADC#TROP2#sac-TMT#港股生物科技#估值
Hold
GFI.US logo
·黄金矿业 ·内部研究

Gold Fields: A De-Rated but Reshaped Global Gold Miner Still Priced for Execution and Country Risk

Gold Fields is a globally diversified gold miner running eight operating mines across South Africa, Ghana, Chile, Peru and Australia plus the Windfall project in Canada, reshaped around the new Salares Norte flagship and the Osisko and Gold Road acquisitions. 2025 delivered a realized gold price of US$3,496/oz, production of 2.438Moz and adjusted free cash flow of US$2.97 billion, yet the US ADR has de-rated quickly from US$38.60 to US$31.88 in a broad gold selloff rather than on any company-specific break. Rating Cautious Buy: an improved but still-cyclical portfolio trading at a discount to peers, where Salares Norte execution and Ghana Tarkwa fiscal terms keep a full-quality rerating away and the ideal buy sits at US$26 to US$29, below the current price.

GFI.US Gold Fields Limited #黄金矿业#黄金#周期股#Salares Norte#储量#估值
Cautious Buy
AU.US logo
·黄金矿业 ·内部研究

AngloGold Ashanti: A Re-Rated Major Gold Miner in Transition, Cash-Rich but Reserve-Light and Priced Near Fair Value

AngloGold Ashanti is a globally diversified major gold miner producing 3.1Moz a year across roughly ten mines, reshaped by the 2024 Centamin/Sukari acquisition and a 2023 redomicile to a UK plc with a primary NYSE listing. 2025 delivered record free cash flow of US$2.9 billion and a year-end adjusted net cash position, but the shares have already re-rated about 69% in a year and a 21.91Moz reserve base implies only about seven years of reserve life against 3.1Moz of annual output. Rating Hold: a much-improved cyclical cash generator now trading near fair value at roughly 0.85x P/NAV, where the easy rerating money has been made and further upside hinges on reserve replacement (Nevada's Arthur) and a gold tape staying generous.

AU.US AngloGold Ashanti plc #黄金矿业#黄金#周期股#Sukari#储量#估值
Hold
B.US logo
·黄金矿业 ·内部研究

Barrick Mining: A World-Class Gold-and-Copper Portfolio in Transition, Discounted for Complexity and Priced Near Fair Value

Barrick Mining is a senior gold-and-copper miner with world-class reserve depth (85Moz gold, 18Mt copper), district quality in Nevada and Pueblo Viejo, and a balance sheet strong enough to fund both record shareholder returns and future growth. Record 2025 cash flow (US$7.69 billion operating, US$3.87 billion free) proved the operating leverage, but the stock trades at a persistent discount to peers because sovereign risk in Mali, a Reko Diq budget review, a Newmont dispute over Nevada, and an unfinished North American carve-out all cloud the path from ore to shareholder value. Rating Hold: the gold cash flows and copper optionality are real, but the price already reflects strong metals and leaves only a moderate cushion against execution risk, with a defensible entry only below roughly US$26.

B.US Barrick Mining Corporation #黄金矿业#Barrick#铜矿#Reko Diq#Nevada Gold Mines#贵金属#估值
Hold
OR.US logo
·贵金属(黄金特许权、流式) ·内部研究

OR Royalties: A Mid-Tier Royalty Franchise Re-Rating With Visible Growth, Priced Around Fair Value

OR Royalties is a mid-tier precious-metals royalty and streaming company anchored by a 3-5% NSR on the Tier-1 Canadian Malartic mine, with 196 interests and 23 producing assets. 2025 revenue jumped 45% to US$277.4 million on a soaring realized gold price and the company finished the year debt-free, while the 2030 outlook of 120,000-135,000 GEOs is backed by named projects rather than blue-sky exploration; yet much of the earnings step-up is gold-price torque and Canadian Malartic still dominates the story. Rating Hold: a genuinely improving franchise re-rating with visible growth, but priced around fair value, with a defensible entry only in the low-to-mid US$20s, below the conservative fair value of US$28.

OR.US OR Royalties Inc. #黄金特许权#OR Royalties#Canadian Malartic#贵金属流式#黄金#加拿大矿业#估值
Hold
1929.HK logo
·黄金珠宝零售 ·内部研究

Chow Tai Fook Jewellery Group: A Scale Leader in Transition, Priced Around Fair Value

Chow Tai Fook is the scale leader in Greater China branded jewellery, with a mostly franchised mainland network and a profit mix tilting toward higher-margin fixed-price gold products. FY2026 revenue rose 5.3% to HK$94.4 billion while operating profit jumped 27.8% to HK$18.85 billion on richer mix and store rationalisation, yet at HK$11.83 the shares sit around the base-case fair value of HK$12.2 with zero margin of safety and an unresolved debate over margin durability. Rating Hold: a cash-generative, scale-leading franchise re-rating on mix and discipline, but priced around fair value, with a defensible entry only below the conservative fair value of HK$9.8.

1929.HK Chow Tai Fook Jewellery Group Limited #黄金珠宝#周大福#定价黄金产品#中国消费#毛利率转型#家族控股#港股#估值
Hold
·工业自动化 ·内部研究

THK: A Category-Defining Linear-Motion Franchise Re-Rated on Restructuring and a Still-Unbooked Robotics Option

THK is the Japanese precision-component maker that commercialized the world's first LM Guide and still leads in linear-motion hardware (LM guides, ball screws, actuators) sold into machine tools, electronics, and factory automation. After exiting a low-return automotive business and adopting an ROE-above-10% policy, continuing-operations earnings are recovering toward 2026 guidance of revenue around 276 billion yen and operating income around 31 billion yen, yet at 7,802 yen the stock trades near 38.5x forward EPS and 3.3x book, pricing in both the restructuring and a robotics optionality the filings do not yet quantify. Rating Hold: a real industrial franchise whose stock has run ahead of delivered execution, with an ideal buy zone of 3,900 to 4,100 yen.

6481.TSE THK Co., Ltd. #Linear Motion#LM Guide#Ball Screw#Industrial Automation#Robot Components#Cyclical#Valuation
Hold
·多元化工业 ·内部研究

Nabtesco: A Scarce Robot-Reducer Franchise Carrying a Growth Premium on a Still-Cyclical Base

Nabtesco is a diversified Japanese precision-machinery group whose profit engine is industrial-robot RV reducers, where it holds about 60% of the global market for medium- to large-joint reducers, backed by transport, aircraft, marine, and door-system businesses. FY2025 continuing-operations sales rose 9.8% and operating income 60.3%, yet at JPY 5,707 the stock trades near record highs at roughly 36x FY2026 EPS and 43x FY2025 EPS, pricing in both the cyclical recovery and a large slice of still-unproven humanoid optionality. Rating Watch: a genuine franchise on a capital-heavy cyclical base, with no margin of safety until the mid-3,000s.

6268.TSE Nabtesco Corporation #精密减速器#RV减速器#工业机器人#人形机器人#多元化工业#周期股#估值
Watch
·精密减速器(谐波减速器·机器人零部件) ·内部研究

Shenzhen Zhaowei: A Real Precision Micro-Drive Business Undergoing a Thematic Robot Re-Rating

Zhaowei is a 25-year-old precision micro-drive systems supplier whose 2025 revenue was RMB1.72 billion, with automotive the real engine at 64.5% of sales while the headline-grabbing embodied-robotics line was just 1.39%. The A-share trades at about 91.5x trailing earnings and the H-share implies a roughly 46.6% discount, so the market is pre-paying for a humanoid-supply-chain future that the filings have not yet delivered. Rating Hold: a credible micro-drive platform with real robot optionality, but the A-share still prices too much of that optionality in advance; the ideal buy zone is CN¥44-61.

003021.SHE Shenzhen Zhaowei Machinery & Electronics Co., Ltd. #精密传动#微型驱动#灵巧手#人形机器人#机器人执行器#汽车零部件#A+H股#估值
Hold
·制药 ·内部研究

Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value

Akeso is a commercial-stage Chinese antibody innovator with seven marketed products and record 2025 commercial sales of RMB3.03 billion, anchored by cadonilimab and ivonescimab. Yet the stock trades as a referendum on one molecule: whether ivonescimab's strong China data (a HARMONi-6 overall-survival win, HR 0.66) can survive global regulators, while 2025 operating cash flow stayed negative at RMB947.6 million and the shares fetch about 22x trailing sales. Rating Hold: rare science and a real China franchise, but the price still pre-pays too much of ivonescimab's ex-China upside; the ideal buy zone is HK$58-64.

9926.HK Akeso, Inc. #创新药#抗体药物#肿瘤免疫(IO)#ivonescimab#双特异性抗体#License-out#港股生物科技#估值
Hold
·AI制药(AI药物发现) ·内部研究

XtalPi Holdings: An AI-for-Science Platform Climbing from Fee-for-Service Work to Milestone Economics, Still Priced Ahead of Proof

XtalPi is a founder-led AI-for-science platform built by MIT-trained physicists, selling drug-discovery and R&D-automation solutions as it tries to climb from fee-for-service work toward milestone-and-royalty economics. 2025 revenue jumped 201.2% to RMB802.6 million as drug-discovery solutions rose to RMB537.9 million from RMB103.7 million, but one customer was over 45% of sales, reported profit leaned on RMB514.0 million of fair-value gains, and operating cash flow stayed negative at RMB-165.4 million. Rating Hold: serious science with blue-chip partners (DoveTree, Lilly, Pfizer) and a large cash cushion, yet the price still pays for cleaner, broader earnings than the platform has delivered; the ideal buy zone is HK$3.8-4.1.

2228.HK XtalPi Holdings Limited #AI制药#AI for Science#药物发现#第18C章#里程碑收入#客户集中度#估值#平台转型
Hold
·医药生产外包(CDMO) ·内部研究

Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success

Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.

002821.SHE Asymchem Laboratories (Tianjin) Co., Ltd. #CDMO#多肽#寡核苷酸#新分子模式#BIOSECURE 政策#A/H 折价#估值#价值投资
Hold
ET.US logo
·能源基础设施 ·内部研究

Energy Transfer LP: A Discounted Midstream Cash Cow Turning Its Asset Empire Into Disciplined Gas-Led Growth

Energy Transfer is a roughly $66bn K-1 master limited partnership that owns about 140,000 miles of integrated U.S. gas, NGL, crude and export infrastructure across 44 states, throwing off $8.20bn of distributable cash flow to partners against a $4.56bn payout, or about 1.8x coverage. Its 2026 EBITDA guidance has been raised twice to $18.2bn-$18.6bn as a gas-and-NGL project backlog converts to cash, yet a 2020 distribution cut, MLP governance frictions and heavy reinvestment keep the units on a roughly 7.1% yield and a persistent structure discount. Rating Hold: integrated bottlenecks support a safe payout and organic reacceleration, but the discount closes only partly until disciplined execution is proven through repetition rather than another deal.

ET.US Energy Transfer LP #中游能源#MLP#天然气#NGL#分红收益#管道基础设施#估值#价值投资
Hold
GGG.US logo
·多元化工业 ·内部研究

Graco Inc.: A Premium Fluid-Handling Compounder Priced for a Recovery Not Yet Visible

Graco is a century-old, distributor-led fluid-handling equipment maker with premium-industrial economics — high-20s operating margins, ~23% ROIC, and ~40% of revenue from parts and accessories. But organic sales fell 6% in Q1 2026 and reported growth now leans on bolt-on M&A (Valco Melton at ~14x EBITDA), while the stock trades near 24.8x earnings with no margin of safety. Rating Hold: a good company at an ordinary price, already priced for a cleaner recovery than the evidence yet shows.

GGG.US Graco Inc. #流体处理设备#工业复利#并购整合#售后零部件#估值#价值投资
Hold
MKSI.US logo
·AI 半导体设备 ·内部研究

MKS Inc.: A Hybrid Process-Control Platform Priced for a Near-Best-Case AI Cycle

MKS is a picks-and-shovels supplier of vacuum, photonics, and materials and chemistry technologies to semiconductor and advanced-packaging manufacturing, reshaped by the 2022 Atotech deal into a hybrid that is part cyclical subsystem vendor and part recurring-chemistry platform. Full-year 2025 revenue reached US$3.93 billion with semiconductor and electronics-and-packaging both growing double digits, and the February 2026 refinancing eased the post-Atotech debt strain, yet at about US$406 the stock trades near 34x trailing EBITDA and 52x non-GAAP earnings. Rating Avoid: a genuinely better business than two years ago, but the price already discounts a near-best-case AI and packaging cycle, with a margin of safety only opening below roughly US$180.

MKSI.US MKS Inc. #半导体设备#先进封装#AI 基础设施#Atotech#估值#周期转型
Avoid
6723.TSE logo
·半导体 ·内部研究

Renesas: A Cyclical Embedded Compounder Priced for a Transition Still Unproven

Renesas is a cyclical embedded-semiconductor compounder centered on automotive MCUs, with analog, power, and connectivity layers and a new system-design software push after Altium. Q1 2026 non-GAAP revenue rose 20.6% to JPY 372.3 billion at a 59.2% gross margin, and 2025 free cash flow reached JPY 328.2 billion, yet IFRS profit swung to a loss on Wolfspeed-related impairments. Rating Hold: a real franchise with better cash than the headlines, but at JPY 4,734 the price already discounts much of the recovery, with a wider margin of safety only opening in the JPY 3,500-3,800 range.

6723.TSE Renesas Electronics Corporation #汽车 MCU#嵌入式半导体#模拟芯片#周期复苏#Altium#估值
Hold
2356.TW logo
·电子制造服务 ·内部研究

Inventec: An AI-Server Manufacturer Still Earning Assembly Margins

Inventec is a Taiwan ODM/EMS maker that has shifted from a notebook-led business to a server-led one, with servers above half of sales on the AI build-out. Q1 2026 revenue rose 28% to NT$200.3 billion, yet gross margin slipped to 5.1% and operating cash flow has converted only about 0.8x of net income over 2021-2025, so AI growth is still monetized through thin, working-capital-heavy assembly economics. Rating Hold: a better business than its old notebook-ODM image, but at NT$67.7 the stock already prices in much of the transition, with a wide margin of safety only opening in the low-to-mid NT$40s.

2356.TW Inventec Corporation #AI server#ODM#EMS#hyperscaler capex#thin margins#valuation
Hold
·精密减速器(谐波减速器·机器人零部件) ·内部研究

Leaderdrive: China's Harmonic-Reducer Leader Priced for a Humanoid Future

Leaderdrive is China's domestic leader in harmonic-drive (strain-wave) reducers, the precision part inside robot joints, now extending from stand-alone components into mechatronic actuators. 2025 revenue jumped 47.3% to RMB 570.7 million with harmonic-reducer unit sales up 72.5%, yet at RMB 381.60 the stock trades near 123x sales and roughly 562x trailing earnings, pre-spending a humanoid-scale future that filings have not yet disclosed. Rating Avoid: a genuinely improving component leader at a speculative price, with every valuation scenario implying a loss from today's level until the humanoid ramp is proven or the price resets.

688017.SHG Leader Harmonious Drive Systems Co., Ltd. #harmonic reducer#precision robotics#humanoid robot#domestic substitution#embodied intelligence#valuation
Avoid
·散热与液冷 ·内部研究

Auras Technology: A Thermal Vendor Climbing the AI Liquid-Cooling Stack

Auras is a Taiwanese thermal-management vendor shifting from legacy air cooling to higher-value AI-server liquid cooling, with 2025 revenue up 47.6% to TWD 23.28 billion. The mix shift is real (2026 Q1 liquid-cooling revenue passed 55% and gross margin reached 29.7%), but 2025 operating cash flow turned negative and the stock near 30.6x trailing earnings already discounts much of the 2026-2027 ramp. Rating Hold: genuine liquid-cooling share gains are visible, yet a wide margin of safety only opens below roughly TWD 690.

3324.TWO Auras Technology Co., Ltd. #thermal management#liquid cooling#AI server#GB300#data center cooling#valuation
Hold
·锂电池与储能 ·In-house Research

LG Energy Solution: Strategic Assets, Unproven Returns

LG Energy Solution is the largest Korean large-format battery maker, running a three-part machine of automotive cells for global OEMs, IRA-localized North American capacity, and a fast-growing energy-storage pivot, with 2025 revenue of ₩23.7tn. The 2026 question is whether it can earn real returns on a ₩42.6tn asset base: Q1 2026 still posted a ₩207.8bn operating loss even after ₩189.8bn of AMPC credits, though 46-series backlog has topped 440 GWh and ESS is becoming a credible second leg. Rating Hold: at ₩404,500 the stock trades near 4.0x sales and already prices a recovery, leaving no clear margin of safety until ex-credit profitability inflects.

373220.KO LG Energy Solution, Ltd. #Battery Manufacturing#Energy Storage#EV Supply Chain#IRA Localization#LFP#Korea#Valuation
Hold
·贵金属(黄金特许权、流式) ·In-house Research

Triple Flag Precious Metals: Quality Compounder, Fully Priced

Triple Flag is a gold-focused streaming and royalty financier that funds miners and collects metal for years at fixed terms, running a 242-asset book at a 93% asset margin with little operating drag. FY2025 revenue reached US$388.7 million with US$312.8 million operating cash flow, yet at US$30.05 the stock trades above its ideal-buy zone, with Northparkes alone at 26% of consensus NAV. Rating Watch: a high-quality compounder still in transition to senior scale, attractive on quality but not yet on price.

TFPM.US Triple Flag Precious Metals Corp. #Gold#Royalty#Streaming#Precious Metals#Compounder#Valuation
Watch
ASAN.US logo
·软件与互联网 ·In-house Research

Asana: Optically Cheap, Strategically Unproven

Asana is a mid-cap, seat-based work-management SaaS now layering consumption-based AI onto a maturing land-and-expand model, with almost all of its $790.8 million FY2026 revenue still tied to the flagship platform. The 2026 story is a clean bull-bear standoff: margins inflected to a $56.7 million FY2026 non-GAAP operating profit and AI products already reached 17% of net-new ARR in Q1 FY2027, yet revenue growth has slowed to high single digits and management still flags PLG as a roughly two-point drag. Rating Watch: the stock is optically cheap at about 1.5x forward EV/revenue, but it needs firmer proof that AI can offset seat-growth maturity before the discount closes.

ASAN.US Asana, Inc. #Work Management#SaaS#AI Monetization#Net Retention#Valuation#Transition
Watch
MRK.XETRA logo
·生命科学工具 ·In-house Research

Merck KGaA: A Diversified Science Platform in Transition

Merck KGaA, Darmstadt is a family-controlled German science-and-technology group whose €21.1 billion of 2025 sales come from three very different engines: a patent-exposed Healthcare arm, a high-quality Life Science tools franchise and a semiconductor-materials Electronics business. The 2026 stock is a tug of war, because a known Mavenclad U.S. patent cliff drags Healthcare while Process Solutions compounds near 10% organically and Electronics rides advanced-node AI demand, leaving the shares near 15.9 times 2025 EPS pre and a 3.5% free-cash-flow yield after a May rebound to €133.05. Rating Hold: genuinely strong Life Science and semiconductor-materials engines offset a credibility-damaged Healthcare arm, but a permanent KGaA governance discount and only-fair valuation keep upside limited.

MRK.XETRA Merck KGaA, Darmstadt, Germany #Life Science Tools#Semiconductor Materials#Pharmaceuticals#KGaA Governance#Conglomerate Discount#Valuation
Hold
SRT3.XETRA logo
·生命科学工具 ·内部研究

Sartorius AG: A Quality Bioprocess Recovery Already in the Price

Sartorius AG is a German life-science tools group whose value is dominated by its majority-owned bioprocess franchise, Sartorius Stedim Biotech, with the liquid quotation being the non-voting preference share SRT3. After a pandemic boom and a destocking bust, 2025 sales recovered 7.6% to about EUR 3.54 billion, underlying EBITDA margin returned to 29.7%, and leverage fell from 3.96x to 3.55x, yet roughly EUR 3.74 billion of net debt and a still-premium 18x trailing EBITDA leave little cushion. Rating Hold: the franchise and the recovery are both real, but the market already sees the normalization and the current EUR 217.10 price sits above the report's ideal buy zone.

SRT3.XETRA Sartorius AG #Sartorius#生物工艺#单次使用耗材#生命科学工具#优先股#去库存周期#估值
Hold
·教育科技 ·内部研究

TAL Education Group: A Cash-Rich Rebuild with a Hardware Question

TAL is a cash-rich China education company rebuilt around legal enrichment classes, learning devices, and content after the 2021 tutoring crackdown. FY2026 revenue reached about US$3.01 billion (up 33.7%) and net cash is roughly US$3.24 billion, but reported earnings are flattered by about US$347 million of non-operating gains and VIEs supplied 78.6% of revenue. Rating Hold: the rebuild is real, yet normalized earnings, device durability, and China-structure risk leave the stock fairly priced rather than compelling.

TAL.US TAL Education Group #TAL#中概教育#双减#VIE#学习硬件#K12素养#估值
Hold